{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-010100","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.967133+00:00","generated_at":"2026-06-05T08:29:01.715810+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ADMA Biologics CFO Brian Lenz steps down; CEO Grossman named interim CFO","bullets":["CFO Brian Lenz transitions to consulting role effective April 1, 2024; consulting agreement through March 31, 2025.","CEO Adam Grossman appointed Interim CFO; executive search initiated for permanent replacement.","Grossman's 2024 base salary set at $800,000; awarded 557,728 RSUs and options for 870,950 shares at $5.40.","Lenz receives $334,875 cash bonus for 2023 performance (141% of corporate goals achieved)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-010100","json":"https://secwatch.observer/filing/0001140361-24-010100.json","markdown":"https://secwatch.observer/filing/0001140361-24-010100.md","text":"https://secwatch.observer/filing/0001140361-24-010100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/0001140361-24-010100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/ef20022642_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:29:01.715810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0f3980c1e","claim":"Brian Lenz changed role as Chief Financial Officer at ADMA BIOLOGICS, INC..","evidence_excerpt":"Effective as of April 1, 2024, Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters, will transition from these positions to a consulting role with the Company (the “CFO Transition”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/0001140361-24-010100-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}